Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis | MicrobiomeTrials← Back to trialsNCT07249840
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-08Est. Completion: 2030-08
Enrollment target: 12 participants Locations- Mass General Brigham, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Myelodysplastic SyndromesMDSMyelodysplastic Syndrome, UnclassifiableHematologic DiseasesBone Marrow DiseaseMyeloproliferative Neoplasm
This study will be conducted as a phase 1/2 study of safety and preliminary efficacy of pacritinib in combination with a…
Multiple LocationsEst. completion Jan 2027
Gastric AdenocarcinomaMetastatic Gastric CancerMetastatic Adenocarcinoma
Advanced Gastric Carcinoma
For patients with advanced/metastatic gastric adenocarcinomas in progression after a first line chemotherapy comprising …
Dijon, FranceCompleted Jun 4, 2026